In “Utility of Molecular Testing in the Diagnostic Workup of Difficult-to-Classify Tumors,” authors Jie-Fu Chen, MD, FCAP, Personalized Healthcare Committee member and JinJuan Yao, MD, PhD, FCAP, outline how advances in genomic, transcriptomic, and epigenetic profiling are helping pathologists navigate some of the most challenging diagnostic scenarios in oncology.
For the full article click here: CAP Highlights Molecular Testing to Clarify Difficult-to-Classify Tumors